A detailed history of Bank Of America Corp transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Bank Of America Corp holds 403,696 shares of BPMC stock, worth $37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
403,696
Previous 335,775 20.23%
Holding current value
$37 Million
Previous $31.9 Million 36.6%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$85.18 - $108.78 $5.79 Million - $7.39 Million
67,921 Added 20.23%
403,696 $43.5 Million
Q1 2024

May 15, 2024

BUY
$73.17 - $99.79 $1.8 Million - $2.45 Million
24,559 Added 7.89%
335,775 $31.9 Million
Q4 2023

Feb 14, 2024

SELL
$43.96 - $92.84 $742,308 - $1.57 Million
-16,886 Reduced 5.15%
311,216 $28.7 Million
Q2 2023

Aug 14, 2023

SELL
$42.2 - $66.37 $3.58 Million - $5.64 Million
-84,921 Reduced 20.56%
328,102 $20.7 Million
Q1 2023

May 12, 2023

BUY
$37.97 - $50.0 $2.92 Million - $3.85 Million
76,942 Added 22.89%
413,023 $18.6 Million
Q4 2022

Feb 10, 2023

BUY
$41.06 - $66.48 $2.39 Million - $3.87 Million
58,227 Added 20.96%
336,081 $14.7 Million
Q3 2022

Nov 14, 2022

SELL
$49.93 - $77.7 $3.66 Million - $5.69 Million
-73,240 Reduced 20.86%
277,854 $18.3 Million
Q2 2022

Aug 12, 2022

SELL
$45.23 - $70.15 $723,544 - $1.12 Million
-15,997 Reduced 4.36%
351,094 $17.7 Million
Q1 2022

May 16, 2022

BUY
$54.1 - $110.08 $4.41 Million - $8.97 Million
81,501 Added 28.54%
367,091 $23.5 Million
Q4 2021

Feb 08, 2022

BUY
$94.25 - $115.99 $2.3 Million - $2.84 Million
24,448 Added 9.36%
285,590 $30.6 Million
Q3 2021

Nov 15, 2021

BUY
$80.98 - $109.47 $209,333 - $282,979
2,585 Added 1.0%
261,142 $26.8 Million
Q2 2021

Sep 13, 2021

BUY
$82.78 - $101.0 $21.4 Million - $26.1 Million
258,557 New
258,557 $22.7 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.48B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.